


*Figure S1: Flow chart of study population*

Table S1: ATC classification and dispensed DAAs among OAT patients in Norway from 2013 to 2017

Description	ATC code
<b>Anti-infective for systemic use</b>	J
Antivirals for treatment of HCV infection, DAAs	J05AP*
Telaprevir	J05AP02
Boceprevir	J05AP03
Faldaprevir	J05AP04
Simeprevir	J05AP05
Asunaprevir	J05AP06
Daclatasvir	J05AP07
Sofosbuvir	J05AP08
Dasabuvir	J05AP09
Ledipasvir and Sofosbuvir	J05AP51
Dasabuvir, ombitasvir, paritaprevir and ritonavir	J05AP52
Ombitasvir, paritaprevir and ritonavir	J05AP53
Elbasvir and grazoprevir	J05AP54
Sofosbuvir and velpatasvir	J05AP55
Sofosbuvir, velpatasvir, and voxilaprevir	J05AP56
Glecaprevir and pibrentasvir	J05AP57
<b>Most prevalent DAAs dispensed in Norway among OAT patients**</b>	
	<b>Frequency (%)</b>
Elbasvir and grazoprevir	328 (27)
Sofosbuvir	279 (23)
Ledipasvir and Sofosbuvir	225 (18)
Sofosbuvir and velpatasvir	187 (15)
Ombitasvir, paritaprevir and ritonavir	55 (5)
Daclatasvir	47 (4)
Dasabuvir	34 (3)
Simeprevir	33 (3)
Other	37 (3)

ATC = Anatomical Therapeutic Chemical classification, OAT = opioid agonist therapy, DAA = direct-acting antivirals

Sources: NorPD = Norwegian Prescription Database

\*Excluding Ribavirin J05AP01

\*\*First registered dispensation by ATC. For sofosbuvir, daclatasvir, dasabuvir and simeprevir additional dispensations of other DAA/antivirals may occur.

*Table S1: Annual and cumulative chronic HCV treatment, crude, among OAT patients in Norway between 2013 and 2017*

	Source	2013	2014	2015	2016	2017	Total
HCV treatment n (overall)	NorPD	146	167	243	322	597	1475
DAAAs, n	NorPD	46	95	212	290	592	1235
DAAAs % of HCV		32	57	87	90	99	84
Study population n, yearly incl. deaths	NorPD	7709	7914	7958	7804	7709	10371
Deaths	NorPD	165	151	138	114	124	692
Study population n, yearly, excl. deaths	NorPD	7544	7763	7820	7690	7585	9679
<b>HCV treatment crude %:</b>							
HCV overall		1.9	2.2	3.1	4.2	7.9	
DAAAs		0.6	1.2	2.7	3.8	7.8	
Cumulative frequency HCV overall		1.9	4.1	7.2	11.4	19.3	
Cumulative frequency DAAAs		0.6	1.8	4.5	8.3	16.1	
95% Confidence interval (HCV)		1.6-2.3	1.8-2.5	2.7-3.5	3.7-4.6	7.3-8.5	
95% Confidence interval (DAAAs)		0.4-0.8	1.0-1.5	2.4-3.1	3.4-4.2	7.2-8.4	

OAT = opioid agonist therapy, HCV = hepatitis C virus, DAA = direct-acting antivirals,  
Sources: NorPD = Norwegian Prescription Database

Table S2: Annual and cumulative chronic HCV treatment coverage among OAT patients in Norway between 2013 and 2017 by Health Regions

	Source:	2013	2014	2015	2016	2017	Total:
Helse Sør-Øst HCV Treatment	NorPD	93	92	158	196	367	906
Helse Vest HCV Treatment	NorPD	24	27	36	64	136	287
Helse Midt HCV Treatment	NorPD	20	18	22	27	52	139
Helse Nord HCV Treatment	NorPD	6	27	27	20	26	106
Study population incl death Helse Sør-Øst	NorPD	4553	4636	4609	4575	4580	
Study population incl death Helse Vest	NorPD	1889	1971	2000	1833	1735	
Study population incl death Helse Midt	NorPD	708	728	731	742	740	
Study population incl death Helse Nord	NorPD	559	578	616	653	653	
Deaths Helse Sør-Øst	NorPD	91	82	84	74	74	
Deaths Helse Vest	NorPD	47	45	33	29	39	
Deaths Helse Midt	NorPD	21	16	10	6	6	
Deaths Helse Nord	NorPD	6	8	11	5	5	
Study population excl death Helse Sør-Øst	NorPD	4462	4554	4525	4501	4506	
Study population excl death Helse Vest	NorPD	1842	1926	1967	1804	1696	
Study population excl death Helse Midt	NorPD	687	712	721	736	734	
Study population excl death Helse Nord	NorPD	553	570	605	648	648	
Prevalence HCV Helse Sør-Øst, mean %	SERAF	55	53	57	52	45	
Prevalence HCV Helse Vest, mean %	SERAF	43	51	50	47	41	
Prevalence HCV Helse Midt, mean %	SERAF	73	53	52	49	36	
Prevalence HCV Helse Nord, mean %	SERAF	45	48	43	33	28	
Prevalence HCV Helse Sør-Øst, n	SERAF	2454	2414	2579	2341	2028	
Prevalence HCV Helse Vest, n	SERAF	792	982	984	848	695	
Prevalence HCV Helse Midt, n	SERAF	502	377	375	361	264	
Prevalence HCV Helse Nord, n	SERAF	238	274	260	214	181	
Incidence HCV Helse Sør-Øst, PWIDs	NIPH, Meijerick et al.	249	233	238	236	238	
Incidence HCV Helse Vest, PWIDs	NIPH, Meijerick et al.	79	93	91	86	81	
Incidence HCV Helse Midt, PWIDs	NIPH, Meijerick et al.	44	39	35	41	33	

Incidence HCV Helse Nord, PWIDs	NIPH, Mejerick et al.	24	23	16	11	15
Incidence HCV Helse Sør-Øst, OAT, n	NIPH, Mejerick et al.	175	163	167	165	167
Incidence HCV Helse Vest, OAT, n	NIPH, Mejerick et al.	55	65	64	60	56
Incidence HCV Helse Midt, OAT, n	NIPH, Mejerick et al.	30	27	25	29	23
Incidence HCV Helse Nord, OAT, n	NIPH, Mejerick et al.	17	16	11	8	10
<i>Treatment coverage HCV Helse Sør-Øst %</i>		3.5	3.5	5.7	7.8	16.7
<i>Cumulative frequency HCV Helse Sør-Øst</i>		3.5	7.1	12.8	20.7	37.4
<i>Treatment coverage HCV Helse Vest %</i>		2.8	2.6	3.4	7.0	18.1
<i>Cumulative frequency HCV Helse Vest</i>		2.8	5.4	8.8	15.9	34.0
<i>Treatment coverage HCV Helse Midt %</i>		3.8	4.4	5.5	6.9	18.1
<i>Cumulative frequency HCV Helse Midt</i>		3.8	8.2	13.7	20.6	38.7
<i>Treatment coverage HCV Helse Nord %</i>		2.4	9.3	9.9	9.0	13.6
<i>Cumulative frequency HCV Helse Nord</i>		2.4	11.7	21.6	30.6	44.2

OAT = opioid agonist therapy, PWID = people who inject drugs, HCV = hepatitis C virus

Sources: NorPD = Norwegian Prescription Database, SERAF = The Norwegian Centre for Addiction Research, NIPH = Norwegian Institute for Public Health, Mejerink et al. (2017): Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030